HK Stock Market Move | Maiwei Biology-B (02493) surged by over 23%, with the clinical research results of 9MW2821 for cervical cancer scheduled to be announced at ESMO GC in 2026.

Maiwei Biotech-B (02493) rose by more than 23%, reaching a new high of 31.46 Hong Kong dollars. As of the time of writing, it has risen by 14.36%, at 29.14 Hong Kong dollars, with a turnover of 1.4 billion Hong Kong dollars. On the news front, on April 28th, Maiwei Biotech was officially listed on the main board of the Hong Kong Stock Exchange and became the first A to H listing company. Since its establishment, the company has obtained approvals for 4 products to be listed and has achieved external authorization for 4 innovative varieties. The core variety 9MW2821 is the second indication globally for urothelial carcinoma, the first indication globally for cervical cancer and triple-negative breast cancer to enter Phase III clinical trials for targeting Nectin-4 ADC, and three Phase III clinical trials are expected to undergo mid-term analysis in the second half of this year, and pre-NDA meetings will be held with the CDE based on the mid-term analysis results. It is worth noting that Maiwei Biotech announced yesterday that the latest clinical research results of the innovative drug 9MW2821 targeting Nectin-4 ADC for cervical cancer will be presented at the 2026 European Society of Medical Oncology Gynecologic Oncology Annual Meeting (ESMO GC) in Copenhagen, Denmark on June 17-19, 2026 in both oral presentation and poster form.